| scholarly article | Q13442814 |
| P2093 | author name string | Fehmi Ateş | |
| Mehmet Yalnız | |||
| Saadet Alan | |||
| P2860 | cites work | Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C | Q27477966 |
| Mechanisms linking obesity to insulin resistance and type 2 diabetes | Q29614887 | ||
| Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis | Q29619627 | ||
| Viral and host causes of fatty liver in chronic hepatitis B | Q35010958 | ||
| Hepatitis C virus-induced hepatocellular steatosis. | Q36060022 | ||
| Steatosis: co-factor in other liver diseases. | Q36165987 | ||
| Therapy of hepatitis B -- viral suppression or eradication? | Q36382226 | ||
| Hepatocellular carcinoma and non-alcoholic fatty liver disease: from a clinical to a molecular association | Q37730153 | ||
| Hepatic steatosis in chronic hepatitis B and C: predictors, distribution and effect on fibrosis | Q42992265 | ||
| Liver steatosis in chronic hepatitis C: a morphological sign suggesting infection with HCV genotype 3. | Q43033577 | ||
| Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients | Q43041131 | ||
| Liver steatosis in patients with chronic hepatitis B infection: host and viral risk factors | Q43503939 | ||
| Hepatic steatosis in chronic hepatitis B patients is associated with metabolic factors more than viral factors | Q44786680 | ||
| Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. | Q45699015 | ||
| Prevalence of liver steatosis in patients with chronic hepatitis B: a study of associated factors and of relationship with fibrosis | Q46931227 | ||
| Steatosis as a predictive factor for treatment response in patients with chronic hepatitis C. | Q50575561 | ||
| Insulin regulation of regional free fatty acid metabolism. | Q54108262 | ||
| Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients | Q57782730 | ||
| Hepatic steatosis has no impact on the outcome of treatment in patients with chronic hepatitis B infection. | Q64936845 | ||
| Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group | Q70542346 | ||
| Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis | Q72638615 | ||
| Histological comparison of chronic hepatitis B and C in an Indian population | Q73845815 | ||
| Host- and disease-specific factors affecting steatosis in chronic hepatitis C | Q77169958 | ||
| Impact of non-alcoholic fatty liver disease on chronic hepatitis B | Q80323339 | ||
| P433 | issue | 40 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | steatosis | Q1365091 |
| pegylated interferon | Q7160835 | ||
| chronic hepatitis B | Q55779876 | ||
| chronic hepatitis | Q62019625 | ||
| P304 | page(s) | 4517-4522 | |
| P577 | publication date | 2011-10-01 | |
| P1433 | published in | World Journal of Gastroenterology | Q15708885 |
| P1476 | title | Impact of liver steatosis on response to pegylated interferon therapy in patients with chronic hepatitis B | |
| P478 | volume | 17 |
| Q37632267 | A noninvasive diagnostic model to assess nonalcoholic hepatic steatosis in patients with chronic hepatitis B. |
| Q54760091 | Controlled Attenuation Parameter as a Noninvasive Method to Detect and Quantify Hepatic Steatosis in Chronic Liver Disease: What Is the Clinical Relevance? |
| Q45206614 | Controlled attenuation parameter for non-invasive assessment of hepatic steatosis: does etiology affect performance? |
| Q46877112 | Controlled attenuation parameter for noninvasive assessment of hepatic steatosis using Fibroscan®: validation in chronic hepatitis B. |
| Q89745437 | Hepatic Steatosis Index in the Detection of Fatty Liver in Patients with Chronic Hepatitis B Receiving Antiviral Therapy |
| Q41019226 | Hepatic Steatosis as a Predictive Factor of Antiviral Effect of Pegylated Interferon Therapy in Patients With Hepatitis B. |
| Q39157327 | Hepatitis B and concomitant hepatic steatosis |
| Q40086892 | High value of controlled attenuation parameter predicts a poor antiviral response in patients with chronic hepatits B. |
| Q42205238 | Metabolic syndrome delays HBeAg seroclearance in Chinese patients with hepatitis B. |
| Q59357606 | Non-alcoholic hepatic steatosis attenuates hepatitis B virus replication in an HBV-immunocompetent mouse model |
| Q43136598 | Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis |
| Q45354091 | Patatin-like phospholipase domain-containing 3 I148M affects liver steatosis in patients with chronic hepatitis B. |
| Q39249655 | The Effect of Hepatosteatosis on Response to Antiviral Treatment in Patients with Chronic Hepatitis B: A Meta-Analysis. |
| Q40584415 | The effects of the insulin resistance index on the virologic response to entecavir in patients with HBeAg-positive chronic hepatitis B and nonalcoholic fatty liver disease |
| Q87047635 | Ultrasonographic quantification of hepatic-renal echogenicity difference in hepatic steatosis diagnosis |
Search more.